Related Experiment Videos

De novo deletion (14)(q11.2q13) including PAX9: clinical and molecular findings

S Schuffenhauer1, H J Leifheit, P Lichtner

  • 1Department of Medical Genetics, Children's Hospital, Ludwig-Maximilians-University Munich, Germany.

Insights

A rare genetic deletion on chromosome 14 (14)(q11.2q13) in a child led to severe developmental issues. This case is the first to report PAX9 hemizygosity, potentially explaining the observed congenital anomalies and swallowing difficulties.

Area of Science:

  • Human Genetics
  • Developmental Biology
  • Clinical Medicine

Background:

  • De novo deletions in humans can lead to complex congenital anomalies.
  • Understanding the genetic basis of developmental disorders is crucial for diagnosis and treatment.
  • The PAX9 gene plays a role in embryonic development, but its role in human congenital disorders is not fully understood.

Observation:

  • A 3-year-old boy presented with a de novo deletion on chromosome 14 (14)(q11.2q13).
  • The deletion encompassed the region from D14S264 to D14S70.
  • Clinical manifestations included severe psychomotor retardation, cleft lip/palate, optic nerve and retinal colobomas, agenesis of the corpus callosum, pes calcaneovarus, reduced esophageal peristalsis, and dysphagia.

Findings:

  • This is the first reported case of PAX9 hemizygosity in humans.
  • The deletion interval was analyzed, and the bZIP transcription factor gene NRL was excluded.
  • The findings suggest PAX9 hemizygosity as a potential cause for the observed developmental defects and dysphagia.

Implications:

  • This case highlights the significance of PAX9 gene haploinsufficiency in human development.
  • Further research into PAX9 function could elucidate mechanisms underlying similar congenital disorders.
  • The study contributes to the understanding of genotype-phenotype correlations in chromosomal deletion syndromes.

Related Concept Videos